Drug main Lupin on Tuesday mentioned it has acquired approval from the US well being regulator for its Albuterol Sulfate Inhalation Aerosol, used for the therapy of acute episodes of bronchospasm or prevention of asthmatic signs. The authorised product is a generic model of ProAir HFA of Teva Branded Pharmaceutical Merchandise R&D, Inc.
In a regulatory submitting, Lupin mentioned it has acquired approval from the US Meals and Drug Administration (USFDA) for its Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuation.
Vinita Gupta, CEO, Lupin mentioned, “The approval is well timed as Albuterol MDI is a key rescue inhalation product for bronchial asthma sufferers who’re at an elevated danger of COVID-19-related issues. We sit up for launching the product this quarter and anticipate a gradual ramp-up by the fiscal 12 months.”
Quoting IQVIA shifting annual complete June 2020 knowledge, Lupin mentioned the full Albuterol Sulfate Inhalation Aerosol market had US gross sales of roughly USD 2.9 billion, of which the ProAir HFA market accounted for USD 1.3 billion.
Shares of Lupin have been buying and selling 0.99 per cent greater at Rs 979.75 apiece on BSE.
(With PTI inputs)
Newest Enterprise Information
Battle in opposition to Coronavirus: Full protection